Antibody production in response to staphylococcal MS-1 phage cocktail in patients undergoing phage therapy

Frontiers in Microbiology

Volumn 7, Issue OCT, 2016, Pages

  Zaczek, Maciej ^a   Łusiak Szelachowska, Marzanna ^a   Jończyk Matysiak, Ewa ^a   Weber Dabrowska, Beata ^a   Miedzybrodzki, Ryszard ^a,b   Owczarek, Barbara ^a   Kopciuch, Agnieszka ^a   Fortuna, Wojciech ^a   Rogóz, Paweł ^a   Górski, Andrzej ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antibodies; Antimicrobials; ELISA; Immune response; Phage cocktail; Phage therapy; Staphylococcal Infections

Indexed keywords

C REACTIVE PROTEIN; DIHYDROXYALUMINUM SODIUM CARBONATE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO PROPAGATION; INFLAMMATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; SEROLOGY; STAPHYLOCOCCUS LUGDUNENSIS; STAPHYLOCOCCUS PHAGE; VIRUS INACTIVATION; VIRUS PURIFICATION;

EID: 84997191035     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2016.01681     Document Type: Article

References (35)

1. Arnold, R. M., Thom, K. A., Sharma, S., Phillips, M., Kristie Johnson, J., and Morgan, D. J. (2011). Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med. J. 104, 40-45. doi: 10.1097/SMJ.0b013e3181fd7d5a.
2. Assasi, N., Blackhouse, G., Campbell, K., Hopkins, R. B., Levine, M., Richter, T., et al. (2015). Comparative Value of Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) Testing in Combination Versus Individually for the Diagnosis of Undifferentiated Patients with Suspected Inflammatory Disease or Serious Infection: A Systematic Review and Economic Analysis. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0084074/pdf/PubMedHealth/_PMH0084074.pdf.
3. Borysowski, J., and Górski, A. (2008). Is phage therapy acceptable in the immunocompromised host? Int. J. Infect. Dis. 12, 466-471. doi: 10.1016/j.ijid.2008.01.006.
4. Bruttin, A., and Brussow, H. (2005). Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49, 2874-2878. doi: 10.1128/AAC.49.7.2874-2878.2005.
5. Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., and Iannelli, D. (2007). Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 51, 2765-2773. doi: 10.1128/AAC.01513-06.
6. Chang, L., Shepherd, D., Sun, J., Ouellette, D., Grant, K. L., Tang, X. C., et al. (2005). Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J. Pharm. Sci. 94, 1427-1444. doi: 10.1002/jps.20364.
7. Cheon, S., Kim, M. J., Yun, S. J., Moon, J. Y., and Kim, Y. S. (2016). Controlling endemic multidrug-resistant Acinetobacter baumannii in intensive care units using antimicrobial stewardship and infection control. Korean J. Intern. Med. 31, 367-374. doi: 10.3904/kjim.2015.178.
8. Chirakadze, I., Perets, A., and Ahmed, R. (2009). "Phage typing, "in Bacteriophages. Methods and Protocols: Molecular and Applied Aspects, Vol. 2, eds M. R. J. Clokie and A. M. Kropinski (New York, NY: Humana Press), 293-305.
9. Dabrowska, K., Miernikiewicz, P., Piotrowicz, A., Hodyra, K., Owczarek, B., Lecion, D., et al. (2014). Immunogenicity studies of proteins forming the T4 phage head surface. J. Virol. 88, 12551-12557. doi: 10.1128/JVI.02043-14.
10. Gobert, A. P., Vareille, M., Glasser, A. L., Hindre, T., de Sablet, T., and Martin, C. (2007). Shiga toxin produced by enterohemorrhagic Escherichia coli inhibits PI3K/NF-kappaB signaling pathway in globotriaosylceramide-3-negative human intestinal epithelial cells. J. Immunol. 178, 8168-8174. doi: 10.4049/jimmunol.178.12.8168.
11. Górski, A., Borysowski, J., Miedzybrodzki, R., and Weber-Dabrowska, B. (2007). "Bacteriophages in medicine, "in Bacteriophage: Genetics and Molecular Biology, eds S. McGrath and D. van Sinderen (Norfolk: Caister Academic Press), 125-158.
12. Górski, A., Miedzybrodzki, R., Borysowski, J., Dabrowska, K., Wierzbicki, P., Ohams, M., et al. (2012). Phage as a modulator of immune responses: Practical implications for phage therapy. Adv. Virus Res. 83, 41-47. doi: 10.1016/B978-0-12-394438-2.00002-5.
13. Górski, A., Wazna, E., Weber-Dabrowska, B., Dabrowska, K., Switala-Jelen, K., and Miedzybrodzki, R. (2006). Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 46, 313-319. doi: 10.1111/j.1574-695X.2006.00044.x.
14. Hentzer, M., Teitzel, G. M., Balzer, G. J., Heydorn, A., Molin, S., Givskov, M., et al. (2001). Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J. Bacteriol. 183, 5395-5401. doi: 10.1128/JB.183.18.5395-5401.2001.
15. Hodyra-Stefaniak, K., Miernikiewicz, P., Drapala, J., Drab, M., Jonczyk-Matysiak, E., Lecion, D., et al. (2015). Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Sci. Rep. 5, 14802. doi: 10.1038/srep14802.
16. Jonczyk-Matysiak, E., Klak, M., Lusiak-Szelachowsk, A. M., Bubak, B., Miedzybrodzki, R., Weber-Dabrowska, B., et al. (2015). The effect of bacteriophage preparations on bone marrow functions and the level of inflammatory markers in blood of patients treated with phage preparations. Poster Presentation at the 21st Evergreen International Phage Meeting. The Evergreen State College, Olympia, WA.
17. Kucharewicz-Krukowska, A., and Slopek, S. (1987). Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz). 35, 553-561.
18. Kurzepa-Skaradzinska, A., Skaradzinski, G., Troszok, A., Weber-Dabrowska, B., Zaczek, M., Maj, T., et al. (2014). "Influence of bacteriophage preparations on migratory activity of human granulocytes in vitro, "in Industrial, Medical and Environmental Applications of Microorganisms: Current Status and Trends, ed. A. Méndez-Vilas (Wageningen: Wageningen Academic Publishers), 529-534. doi: 10.3920/978-90-8686-795-0.
19. Leekha, S., Terrell, C. L., and Edson, R. S. (2011). General principles of antimicrobial therapy. Mayo Clin. Proc. 86, 156-167. doi: 10.4065/mcp.2010.0639.
20. Lusiak-Szelachowska, M., Annabhani, A., Weber-Dabrowska, B., Górski, A., Bebenek, M., Pudelko, M., et al. (2008). Escherichia coli bacteriophages in human stool of patients with gastrointestinal tract diseases. Gastroenterol. Pol. 15, 87-90.
21. Lusiak-Szelachowska, M., Zaczek, M., Weber-Dabrowska, B., Klak, M., Miedzybrodzki, R., Fortuna, W., et al. (2016). "Antiphage activity of sera from patients receiving staphylococcal phage preparations, "in Microbes in the Spotlight: Recent Progress in the Understanding of Beneficial and Harmful Microorganisms, ed. A. Méndez-Vilas (Boca Raton, FL: BrownWalker Press), 245-249.
22. Lusiak-Szelachowska, M., Zaczek, M., Weber-Dabrowska, B., Miedzybrodzki, R., Klak, M., Fortuna, W., et al. (2014). Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27, 295-304. doi: 10.1089/vim.2013.0128.
23. Majewska, J., Beta, W., Lecion, D., Hodyra-Stefaniak, K., Klopot, A., Kazmierczak, Z., et al. (2015). Oral Application of T4 phage induces weak antibody production in the gut and in the blood. Viruses 7, 4783-4799. doi: 10.3390/v7082845.
24. Miedzybrodzki, R., Borysowski, J., Weber-Dabrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., et al. (2012). Clinical aspects of phage therapy. Adv. Virus Res. 83, 73-121. doi: 10.1016/B978-0-12-394438-2.00003-7.
25. Miedzybrodzki, R., Fortuna, W., Weber-Dabrowska, B., and Górski, A. (2009). A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin. Exp. Med. 9, 303-312. doi: 10.1007/s10238-009-0044-2.
26. Miura, K., Orcutt, A. C., Muratova, O. V., Miller, L. H., Saul, A., and Long, C. A. (2008). Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26, 193-200. doi: 10.1016/j.vaccine.2007.10.064.
27. Pescovitz, M. D., Torgerson, T. R., Ochs, H. D., Ocheltree, E., McGee, P., Krause-Steinrauf, H., et al. (2011). Effect of rituximab on human in vivo antibody immune responses. J. Allergy Clin. Immunol. 128, 1295-1302. doi: 10.1016/j.jaci.2011.08.008.
28. Saadeh, C. (1998). The erythrocyte sedimentation rate: old and new clinical applications. South. Med. J. 91, 220-225. doi: 10.1097/00007611-199803000-00001.
29. Sarker, S. A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F., et al. (2016). Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine. 4, 124-137. doi: 10.1016/j.ebiom.2015.12.023.
30. Slopek, S., Durlakowa, I., Weber-Dabrowska, B., Kucharewicz-Krukowska, A., Dabrowski, M., and Bisikiewicz, R. (1983). Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. 31, 267-291.
31. Stashak, P. W., Baker, P. J., and Roberson, B. S. (1970). The serum antibody response to bacteriophage phiX174 in germ-free and conventionally reared mice. II. Kinetics of the serum antibody response following primary immunization. Immunology 18, 307-317.
32. Sulakvelidze, A., Alavidze, Z., and Morris, J. G. Jr. (2001). Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649-659. doi: 10.1128/AAC.45.3.649-659.2001.
33. Sulakvelidze, A., and Barrow, P. (2005). "Phage therapy in animals and agribusiness, "in Bacteriophages. Biology and Application, eds E. Kutter and A. Sulakvelidze (Boca Raton, FL: CRC Press), 335-380.
34. Szermer-Olearnik, B., and Boratynski, J. (2015). Removal of endotoxins from bacteriophage preparations by extraction with organic solvents. PLoS ONE 10:e0122672. doi: 10.1371/journal.pone.0122672.
35. Weber-Dabrowska, B., Zaczek, M., Dziedzic, B., Lusiak-Szelachowska, M., Kiejzik, M., Górski, A., et al. (2014). "Bacteriophages in green biotechnology-the utilization of drinking water, "in Industrial, Medical and Environmental Applications of Microorganisms: Current Status and Trends, ed. A. Méndez-Vilas (Wageningen: Wageningen Academic Publishers), 500-504. doi: 10.3920/978-90-8686-795-0.